Wake up daily to our latest coverage of business done better, directly in your inbox.
Get your weekly dose of analysis on rising corporate activism.
The best of solutions journalism in the sustainability space, published monthly.
Select Newsletter
By signing up you agree to our privacy policy. You can opt out anytime.
Pharmaceutical giant Merck is to donate millions of vaccines and testing resources for the prevention of cervical cancer in Africa.
Under the terms of a partnership with Dutch diagnostics company Quiagan, the US-based firm will provide two million doses of its human papillomaviros (HPV) Gardasil vaccine and 250,000 HPV tests for a national prevention programme in Rwanda.
After three years, Merck will offer the drugs to Rwanda at a ‘dramatically’ discounted but unspecified price.
Merck will also provide equipment and training to institute the screening of 35- to 45-year-old women and distribute the vaccines, which will be routinely supplied to 12- to 15-year-olds.
Launching the first prevention programme of its kind in Africa, the Rwandan minister of health said: “This program brings us one step closer to reaching our goal of protecting the girls and women in our country.”
TriplePundit has published articles from over 1000 contributors. If you'd like to be a guest author, please get in touch!
